WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

Walaa Younes Jamoua*, Maison Dayoub and Ahmad Yousef

ABSTRACT

Background: Misoprostol is a prostaglandin E-1 analogue which induces uterine contractions and cervical dilatation to reduce primary cesarean section and improve final outcome regarding subsequent pregnancies. Aim: The purpose of this study was to evaluate the effectiveness of different doses of vaginal misoprostol for medical induction of labor and compare the side effects of the two doses. Materials and Methods: A Prospective study conducted for the period one year (2022- 2023) at Tishreen University Hospital in Lattakia-Syria. The study included 100 pregnant women at full term who had indication for induction of labor, and were divided into group A (50): women were administrated 25 µg of vaginal misoprostol, and group B(50): women were administrated 50 µg of vaginal misoprostol. Results: The mean age was 26.33±1.88 years, without significant differences between the two groups regarding age, gestational age, obstetric history, body mass index, status of cervix, etiology of labor induction, and mean induction -abortion interval. The rate of induction success was 88% in group A versus 94% in group B without significant difference, p:0.6. Vaginal delivery was observed more frequently in group B(78% versus 74%, P:0.2) without presence of significant difference between two groups regarding complications (p> 0.05). The rate of responsive to induction was higher in pregnant women in the following cases: advanced age, low body mass index, gestational age group (40-42 weeks), Bishop score (5-6) and multiparous but without significant difference(p>0.05). Conclusion: Our study findings suggest that misoprostol in low dose represents a safe and effective alternative to high doses for induction of labor at full term.